Systemic Lupus Erythematosus Flare Management
A 29-year-old woman with systemic lupus erythematosus taking mycophenolate mofetil develops a malar rash, temperature 38.1 °C, and painful swelling of both wrists over one week. Blood and urine cultures are negative, creatinine is 68 µmol/L, urinalysis shows no protein or cellular casts, C3 and C4 are mildly reduced, and anti-double-stranded DNA titres are rising. Which is the most appropriate addition to her treatment?
- A.Pulse intravenous cyclophosphamide therapy
- B.Weekly oral methotrexate therapy
- C.Daily oral azathioprine therapy
- D.Hydroxychloroquine and low-dose prednisoneCorrect
Explanation
This is a mild to moderate lupus flare confined to skin and joints with normal renal function and a bland urinary sediment, so treatment is escalated proportionately rather than with cytotoxic therapy. The EULAR 2023 recommendations advise hydroxychloroquine for all patients with systemic lupus erythematosus at a target dose of 5 mg/kg actual body weight daily, because it controls mucocutaneous and articular disease, reduces flares and damage accrual, lowers thrombotic risk, and improves survival, yet it is frequently omitted. Glucocorticoid is used as bridging therapy while hydroxychloroquine takes 6 to 12 weeks to act, given at the lowest effective dose and tapered towards 5 mg daily or less, or withdrawn. Severity drives choice of agent: mild flares need antimalarials with or without low-dose glucocorticoid, moderate flares need a short course of moderate-dose prednisone with an immunosuppressant, and organ-threatening flares such as proliferative lupus nephritis, neuropsychiatric disease, or severe cytopenias require pulse methylprednisolone plus cyclophosphamide, mycophenolate, rituximab, or belimumab. The normal creatinine, absent proteinuria, and clear sediment exclude active nephritis and therefore exclude cyclophosphamide. Mildly low complement with rising anti-double-stranded DNA indicates serological activity but does not by itself justify cytotoxic escalation. Switching mycophenolate for methotrexate or azathioprine abandons an agent she has not yet failed and is a lateral or downward move. Infection must always be excluded in a febrile immunosuppressed patient with lupus before immunosuppression is intensified, which is why cultures are checked first.
Why each option
- A.
- Cyclophosphamide is reserved for organ-threatening disease such as proliferative lupus nephritis or neuropsychiatric lupus, and her renal indices are normal.
- B.
- Methotrexate is an option for refractory lupus arthritis, but replacing mycophenolate before it has failed is not appropriate first escalation.
- C.
- Azathioprine is a steroid-sparing agent for moderate disease and is generally less potent than the mycophenolate she already takes.
- D.
- Correct. A mild to moderate skin and joint flare is treated with hydroxychloroquine plus a short course of low-dose prednisone as bridging therapy.
Reference: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update, Ann Rheum Dis 2024;83:15-29
This is one of 3,009 questions in the MedBoardSA SMLE bank, with timed test mode, tutor mode, and progress tracking by topic.
Practise the full bank